Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.

Tosolini AP, Sleigh JN.

Front Mol Neurosci. 2017 Dec 7;10:405. doi: 10.3389/fnmol.2017.00405. eCollection 2017. Review.

2.

αCAR IGF-1 vector targeting of motor neurons ameliorates disease progression in ALS mice.

Eleftheriadou I, Manolaras I, Irvine EE, Dieringer M, Trabalza A, Mazarakis ND.

Ann Clin Transl Neurol. 2016 Sep 7;3(10):752-768. eCollection 2016 Oct.

3.

MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis.

Glajch KE, Ferraiuolo L, Mueller KA, Stopford MJ, Prabhkar V, Gravanis A, Shaw PJ, Sadri-Vakili G.

PLoS One. 2016 Oct 7;11(10):e0164103. doi: 10.1371/journal.pone.0164103. eCollection 2016.

4.

The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS.

Brahimi F, Maira M, Barcelona PF, Galan A, Aboulkassim T, Teske K, Rogers ML, Bertram L, Wang J, Yousefi M, Rush R, Fabian M, Cashman N, Saragovi HU.

PLoS One. 2016 Oct 3;11(10):e0162307. doi: 10.1371/journal.pone.0162307. eCollection 2016.

5.

Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

Garbuzova-Davis S, Thomson A, Kurien C, Shytle RD, Sanberg PR.

Expert Rev Neurother. 2016 Dec;16(12):1397-1405. Epub 2016 Jul 15. Review.

6.

Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.

Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N.

Hum Gene Ther. 2016 Jul;27(7):478-96. doi: 10.1089/hum.2016.087. Review.

7.

Pharmacology of manipulating lean body mass.

Sepulveda PV, Bush ED, Baar K.

Clin Exp Pharmacol Physiol. 2015 Jan;42(1):1-13. doi: 10.1111/1440-1681.12320. Review.

8.

Antioxidant gene therapy against neuronal cell death.

Navarro-Yepes J, Zavala-Flores L, Anandhan A, Wang F, Skotak M, Chandra N, Li M, Pappa A, Martinez-Fong D, Del Razo LM, Quintanilla-Vega B, Franco R.

Pharmacol Ther. 2014 May;142(2):206-30. doi: 10.1016/j.pharmthera.2013.12.007. Epub 2013 Dec 12. Review.

9.

Progress in gene therapy for neurological disorders.

Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ, Wolfe JH, Glorioso JC.

Nat Rev Neurol. 2013 May;9(5):277-91. doi: 10.1038/nrneurol.2013.56. Epub 2013 Apr 23. Review. Erratum in: Nat Rev Neurol. 2013 Jun;9(6):298.

10.

Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application.

Benkler C, Offen D, Melamed E, Kupershmidt L, Amit T, Mandel S, Youdim MB, Weinreb O.

EPMA J. 2010 Jun;1(2):343-61. doi: 10.1007/s13167-010-0026-1. Epub 2010 Jun 29.

11.

Viral vectors and delivery strategies for CNS gene therapy.

Gray SJ, Woodard KT, Samulski RJ.

Ther Deliv. 2010 Oct;1(4):517-34. Review.

12.

Stem cell therapy for the spinal cord.

Donnelly EM, Lamanna J, Boulis NM.

Stem Cell Res Ther. 2012 Jul 9;3(4):24. doi: 10.1186/scrt115. Review.

13.
14.

Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase.

Audet JN, Gowing G, Paradis R, Soucy G, Julien JP.

PLoS One. 2012;7(4):e34932. doi: 10.1371/journal.pone.0034932. Epub 2012 Apr 16.

15.

Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis.

Wang DB, Gitcho MA, Kraemer BC, Klein RL.

Eur J Neurosci. 2011 Oct;34(8):1179-88. doi: 10.1111/j.1460-9568.2011.07803.x. Epub 2011 Jul 21. Review.

16.

Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice.

Towne C, Setola V, Schneider BL, Aebischer P.

Mol Ther. 2011 Feb;19(2):274-83. doi: 10.1038/mt.2010.260. Epub 2010 Nov 23.

17.

Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Henriques A, Pitzer C, Schneider A.

Front Neurosci. 2010 Jun 11;4:32. doi: 10.3389/fnins.2010.00032.

18.

Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Lim ST, Airavaara M, Harvey BK.

Pharmacol Res. 2010 Jan;61(1):14-26. doi: 10.1016/j.phrs.2009.10.002. Epub 2009 Oct 17. Review.

19.

A conditioning lesion provides selective protection in a rat model of Amyotrophic Lateral Sclerosis.

Franz CK, Quach ET, Krudy CA, Federici T, Kliem MA, Snyder BR, Raore B, Boulis NM.

PLoS One. 2009 Oct 6;4(10):e7357. doi: 10.1371/journal.pone.0007357.

Supplemental Content

Support Center